SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors debate whether the current price action signals a sustainable breakout or another temporary pump, with community sentiment sharply divided between long-term believers and vocal skeptics. Discussions are centered on the token's relationship with broader market movements and speculative hopes for future regulatory clarity and institutional adoption.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc is currently seeing significant market activity and high trading volume as investors position themselves ahead of the May 31 PDUFA date for its ADHD treatment, CTx-1301. The community is heavily focused on potential near-term US patent approvals, with many traders drawing comparisons to historical price action following international patent milestones and expressing strong conviction in the stock's long-term commercial potential.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

GODS token is the currency used in the blockchain-based online trading card game, Gods Unchained. The token will act as a governance so players will be able to decide the development direction of the game. Players can also use the token to mint rare cards. Most importantly, the GODS token will be an integral part of the play to earn concept of the game.

Gods Unchained

Gods Unchained is trending as the community speculates on a potential price breakout, citing its gaming utility and low market capitalization relative to peers as catalysts. Traders are actively debating technical patterns like the cup-and-handle and monitoring for a broader rotation into the gaming sector, with many expressing optimism for long-term growth and high-percentage gains.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors debate whether potential integration into Xs upcoming payment system serves as a long-term catalyst or just a temporary pump. While some community members remain skeptical, citing historical price patterns and bearish sentiment, others are actively loading up on shares in anticipation of a significant breakout.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant volatility and high trading volume following the release of promising Phase 1 expansion data for its colorectal cancer treatment, Varsetatug Masetecan. While bulls are energized by positive clinical signals and analyst price target upgrades, the community is actively debating the impact of the newly announced public offering and the long-term dilution risks inherent in clinical-stage drug development.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid a surge in institutional activity, highlighted by a notable streak of daily inflows into newly launched spot ETFs that continues to attract retail attention. Despite ongoing volatility and community debates over its long-term utility versus market speculation, holders remain focused on the potential impact of global regulatory milestones and increased banking partnerships on future liquidity.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the stock sustains bullish momentum, driven by positive analyst upgrades and investor optimism regarding the company's expanding EV lineup and integrated AI chip technology. The community is actively debating the potential for a short squeeze as share prices test major resistance levels, with many long-term shareholders holding firm in anticipation of a significant revaluation.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified in the patient who died, the FDA said.&nbsp;</li><li>The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma.</li><li>The agency noted that neutralizing antibodies were not reported in clinical trials.</li></ul>The U.S. Food and Drug Administration (FDA) said on Friday that it is investigating the death of a patient treated with Adzynma.Adzynma, a man-made enzyme therapy manufactured by Takeda Pharmaceuticals (TAK), is approved for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome. It is a rare inherited disorder characterized by a severe deficiency of the ADAMTS13 enzyme.The death of a pediatric cTTP patient appears to be related to Adzynma, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-death-due-neutralizing-antibodies-adamts13-following-adzynma-treatment-congenital">said</a>.<h2 class="st-heading-2">Findings And Further Probe</h2>Before starting Adzynma treatment, the patient had severe allergic reactions to fresh frozen plasma, the FDA noted. After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified.However, the agency also noted that current assays cannot differentiate the neutralizing antibodies to man-made enzyme therapy from the neutralizing antibodies to the body’s own enzymes. The agency also added that it has received other reports of neutralizing antibodies in patients treated with the drug since approval.The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma. The agency noted that neutralizing antibodies were not reported in clinical trials and that the current labeling does not include the risk of serious and fatal outcomes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TAK stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/TAK">TAK stock</a> has gained 8% this year and about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Takeda Pharmaceutical Company, building exterior with company sign, 500 Kendall Street, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 

Equity

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 


Retail sentiment around Anheuser-Busch InBev (ABI),&nbsp;the maker of Budweiser and Corona beers, ticked higher, even as a weak quarterly report sent its shares sliding on Thursday.<a href="https://stocktwits.com/symbol/BUD">BUD's U.S.-listed shares</a> dropped over 13%&nbsp;in the previous session, marking their worst day in over five years.On Stocktwits, retail sentiment&nbsp;shifted to 'extremely bullish' by early Friday, up from 'bullish' the day before, as traders&nbsp;viewed the slide as an overreaction and saw it as a buying opportunity. Message volume for BUD rose 1,200% in the past 24-hour period, among the highest for a consumer stock.<figure class="image"><img style="aspect-ratio:1256/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_12_48_05_PM_png_fd95800c98.webp" alt="Screenshot 2025-08-01 at 12.48.05 PM.png" width="1256" height="156"><figcaption>BUD sentiment and message volume as of August 1 | Source: Stocktwits</figcaption></figure>"Not a fan of the company, but this drop is a bit unjustified," said one user<stembedurl>https://stocktwits.com/Reddiot/message/623258303</stembedurl>Another said: "$BUD Buying dat dip, 10% discount? Thank you!" A third user shared a technical chart showing the stock hitting a key long-term support level.<stembedurl>https://stocktwits.com/stocksailor23/message/623228047</stembedurl><stembedurl>https://stocktwits.com/theoptionsplug/message/623173574</stembedurl>AB InBev said revenue grew 3% organically in the second quarter, below market expectations of 3.2% growth. Organic sales volumes, however, were down 1.9%,&nbsp;primarily due to weak sales in Brazil and China, marking the&nbsp;ninth consecutive quarter of declining beer sales.&nbsp;That was significantly below the 0.3% decline analysts had expected.Organic operating profit increased by 6.5%, ahead of analysts' forecasts of 5.7%.The world's largest brewer also reported weaker-than-expected volumes in Europe and the Middle East,&nbsp;which led to disappointment in all regions except North America.A rebound in the home market comes even as beer demand softens in the region. Bank of America has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bof-a-downgrades-miller-lite-brewer-molson-coors-amid-softness-in-us-beer-sales/chmZESFRReS">predicted</a> that U.S. beer volumes will shrink by 4% next year, steeper than its earlier prediction of 1% decline.In early July, AB InBev&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/budweiser-maker-ab-inbev-plans-300m-investment-to-expand-us-production/chi8fifRbZd">announced</a> plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Starbucks-china-operations-jd-tencent-kkr-among-potential-investors/chr3YU9RdGt">Starbucks China Operations: JD, Tencent, KKR Among Potential Investors To Submit Bids - Report</a>

In this photo illustration, Budweiser beer bottles are seen displayed. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'

U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.

Anheuser-Busch InBev (BUD) on Monday announced plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.As part of the investment, the brewer of the popular Budweiser beer will also set up a new plant in Columbus, Ohio."Anheuser-Busch has been a shining example of what 'Made in America' means, and their latest investment of $300 million builds on their longtime commitment to grow our workforce and expand U.S. manufacturing," U.S. Labor Secretary Lori Chavez-DeRemer said, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.anheuser-busch.com/newsroom/anheuser-busch-announces-new-300-million-investment-in-manufacturing-operations-across-the-US">statement</a> from the company on Monday.The company earlier stated it was increasing investment in core brands like Budweiser and focusing more on driving at-home consumption, as spending in venues like bars continues to face pressure.Anheuser-Busch is originally an American company, founded in St. Louis, Missouri, which remains the home of its U.S. operations.Anheuser-Busch and a Belgian-Brazilian beverage conglomerate InBev merged in 2008 to form Anheuser-Busch InBev or AB InBev.On Stocktwits, the retail sentiment turned to 'bullish' from 'neutral' the previous day.<figure class="image"><img style="aspect-ratio:568/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_00_47_PM_png_61e53222de.webp" alt="Screenshot 2025-05-13 at 1.00.47 PM.png" width="568" height="62"><figcaption>BUD sentiment and message volume as of May 12 | Source: Stocktwits</figcaption></figure>A bullish user said they were "all in on $BUD" because of its global presence and partnerships with key events, including the World Cup.<stembedurl>https://stocktwits.com/bullbearpro/message/614331283</stembedurl>The company's U.S.-listed shares are up 32.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

JSTC
Tidal ETF Trust - Adasina Social Justice All Cap Global ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest JSTC News

JSTCTidal ETF Trust - Adasina Social Justice All Cap Global ETF